Azarakhsh Baghdadi

Dr. Azarakhsh Baghdadi

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2022 in HPB
Verified
Journal Article
Closed access
ZBZachary J. Brown
Zachary J. Brown
ABAzarakhsh Baghdadi
Azarakhsh Baghdadi
IKIhab Kamel
Ihab Kamel
HLHanna E. Labiner
Hanna E. Labiner
DHD. Brock Hewitt
D. Brock Hewitt
Tim PawlikTim Pawlik
Tim Pawlik

15 January 2021 in BMC Rheumatology
Verified
Journal Article
Open access
PDF file
MKMina Kiafar
Mina Kiafar
SFSeyedeh Tahereh Faezi
Seyedeh Tahereh Faezi
AKAmir Kasaeian
Amir Kasaeian
ABAzarakhsh Baghdadi
Azarakhsh Baghdadi
SKSahar Kakaei
Sahar Kakaei
FDFereydoun Davatchi
Fereydoun Davatchi
Background: The diagnosis of Behçet disease (BD) is challenging in many cases. The purpose of this study was to describe the clinical characteristics of patients at a referral BD clinic. Methods: In a retrospective study, we collected data from patients at a national referral Behçet clinic from November 2018–August 2019. A BD diagnosis was confirmed (BD group) or ruled out (Non-BD group), and the two groups were compared for differences. Results: A total of 238 patients satisfied the inclusion criteria. Forty patients (16.8%) were finally diagnosed with BD. Ocular and genital lesions were significantly more prevalent in the BD group. A positive pathergy test and HLA-B51 were also significantly more common in BD. However, oral lesions, articular involvement, and gastrointestinal manifestations were similar between groups. Also, patients with BD were significantly more likely to have multi-organ (≥2 organ systems) involvement. Conclusions: Being the first study to evaluate the clinical characteristics of patients who are visited at a referral BD clinic and are believed to have a high probability of Behçet, the results of this study are important from an epidemiological standpoint. Also, the findings of this study could be used by referral Behçet clinics, which evaluate and diagnose patients with a high pretest probability and atypical presentations of BD on a daily basis. The alternative diagnoses established in this study could be used as the list of the most common differential diagnoses for Behçet’s disease.

30 October 2022 in Cancers
Verified
Journal Article
Open access
PDF file
KCKrista Y. Chen
Krista Y. Chen
APAleksandra Popovic
Aleksandra Popovic
DHDavid Hsiehchen
David Hsiehchen
MBMarina Baretti
Marina Baretti
PGPaige Griffith
Paige Griffith
MYMark Yarchoan
Mark Yarchoan
Background: Fibrolamellar hepatocellular carcinoma (FLC) is a rare form of liver cancer primarily affecting children and young adults. Although considered a subset of hepatocellular carcinoma (HCC), FLC has unique molecular and pathologic characteristics, suggesting that it may require different treatment. Immune checkpoint inhibitors (ICIs) are used in the treatment of HCC, but efficacy and safety in FLC has not been characterized. Methods: We performed a multicenter retrospective analysis of patients with FLC to determine responses to ICI therapy. Response rates were assessed based on RECIST 1.1 criteria, and Kaplan–Meier statistics were used for progression-free survival (PFS) and overall survival (OS). Results: FLC tumors were characterized by low tumor mutational burden (TMB) and absent PD-L1 expression. We identified 19 patients who received ICIs, including 15 who received ICI therapy alone [programmed death receptor 1 (PD-1) inhibitor, +/− cytotoxic T lymphocyte antigen-4 (CTLA-4) inhibitor]. Objective tumor responses were observed in 3/19 patients (15.8%), including 2/15 patients (13.3%) who received ICIs alone, all partial responses. Median PFS and OS were 5.5 and 26.0 months, respectively. Grade 3–4 immune related adverse events were observed in 4/19 (21.1%) patients. Conclusions: ICI therapy has modest clinical activity in FLC, and novel therapeutic combinations are needed.

1 October 2021 in BMC Rheumatology
Verified
Journal Article
Open access
PDF file
HBHamidreza Bashiri
Hamidreza Bashiri
NKNooshin Karimi
Nooshin Karimi
SMShayan Mostafaei
Shayan Mostafaei
ABAzarakhsh Baghdadi
Azarakhsh Baghdadi
MNMohammad Nejadhosseinian
Mohammad Nejadhosseinian
SFSeyedeh Tahereh Faezi
Seyedeh Tahereh Faezi
Background: Ocular manifestations are common in systemic lupus erythematosus (SLE). Retinopathy has previously been linked to disease severity and might have a significant impact on the patient’s quality of life and has also been associated with a poor prognosis in SLE. This study aimed to determine the prevalence of retinopathy among patients who are newly diagnosed with SLE. Methods: In a cross-sectional study, patients diagnosed with SLE at a tertiary referral clinic were assessed for inclusion between March 2016 and March 2017. Patients who had received treatment for SLE at any time were excluded, as well as patients with hypertension, diabetes mellitus, and coagulopathy. Clinical findings and laboratory test results were recorded, and patients were examined by an ophthalmologist for evidence of retinal pathologies. SLE disease activity index was also calculated for all patients. Results: With 114 patients included in the final analysis, we found a prevalence of 15.8% for retinopathy among newly-diagnosed SLE patients. Cotton-wool spots were the most common finding (78%). Patients with retinopathy had significantly lower hemoglobin levels, C3 and C4 concentrations, and higher ANA and Anti-dsDNA levels. Also, patients with retinopathy had a significantly higher SLE DAI score. Conclusions: We found a relatively high rate of retinopathy in SLE patients at the time of their initial diagnosis. Our findings suggest that retinopathy is an early manifestation of the disease. Ophthalmologic screening might be considered for SLE patients at the time of diagnosis, especially for those with severe disease. We also encourage researchers to further evaluate the correlation between retinopathy and disease activity, and the prognosis of ocular involvement.

27 September 2023 in Rheumatology
Verified
Journal Article
Open access
ADAli Dehghan
Ali Dehghan
HSHamidreza Soltani
Hamidreza Soltani
SFSeyedeh Tahereh Faezi
Seyedeh Tahereh Faezi
ABAzarakhsh Baghdadi
Azarakhsh Baghdadi
HSHossein Soleymani Salehabadi
Hossein Soleymani Salehabadi
MNMohammad Nejadhosseinian
Mohammad Nejadhosseinian
Introduction: Systemic lupus erythematosus (SLE) is a multisystem disorder that can affect multiple organs; psy-chiatric manifestations including depression and anxiety are commonly seen in SLE. The aim of this study is to explore the prevalence of depression, anxiety, and stress, and assess the quality of life (QOL) in patients with SLE and also evaluate associated risk factors.Material and methods: In this cross-sectional study, adult patients with SLE were identified through our institution’s SLE data registry. Participants were evaluated with three questionnaires: Depression, Anxiety, and Stress Scale (DASS-42), General Health Ouestionnaire-28 (GHQ-28), and World Health Organization quality of life instrument short form (WHO-QOL BREF).Results: A total of 222 patients were included in the study, 203 (91%) of whom were female and 19 were male (9%). Participants had a mean age of 35.6 ±9.5 years. According to DASS-42 question-naire, 22.1%, 28.7% and 20.3% of patients had varying degrees of depression, anxiety, and stress, respectively. Based on GHQ-28 questionnaire, 137 (62%) of patients reported some degree of distress. Quality of life score was 12.8, 13, 14.3, and 13.9 in physical health, psychological health, social relationships, and environmental health, respectively.Conclusions: We found that depression, anxiety, and stress are common in patients with SLE, and quality of life is significantly affected. A high percentage of patients with SLE deal with some degree of distress. Rou-tine evaluation of the quality of life and psychological disturbances is recommended in patients with SLE. Non-pharmacological interventions as well as specialist referral should be considered in patients with anxiety, depression, or stress.

27 April 2021 in Rheumatology
Verified
Journal Article
Open access
ZSZahra Soltani
Zahra Soltani
ABAzarakhsh Baghdadi
Azarakhsh Baghdadi
MNMohammad Nejadhosseinian
Mohammad Nejadhosseinian
SFSeyedeh Tahereh Faezi
Seyedeh Tahereh Faezi
BSBijan Shahbazkhani
Bijan Shahbazkhani
KKKiarash Kazemi
Kiarash Kazemi
Introduction: Celiac disease (CD) is one of the most common chronic diseases. Celiac disease has been associated with several autoimmune disorders, but the association with systemic lupus erythematosus (SLE) as a systemic autoimmune disease is still controversial. In this study, we aimed to determine the prevalence of biopsy-proven CD in patients with SLE, and to determine the clinical symptoms and laboratory data in these patients.Material and methods: In a cross-sectional study, SLE patients at a referral clinic were evaluated for gastrointestinal symptoms between March and December 2016. Patients were evaluated by a gastroenterologist, and upper gastrointestinal endoscopy with intestinal biopsy was performed if deemed necessary. The clinical symptoms, laboratory data, and endoscopy results were recorded and compared between groups.Results: In total, 130 patients were evaluated in this study. Gastrointestinal symptoms were present in 40% of the patients. Endoscopy was performed in all SLE patients with gastrointestinal symptoms. Four patients (3%) were diagnosed as having CD based on biopsy results and response to a gluten-free diet. Anti-endomysium antibody (AEA) was found to be 100% sensitive and 99.2% specific for the diagnosis of CD in SLE patients, and anti-gliadin antibody (AGA) had a 50% sensitivity and 98% specificity. Patients with comorbid CD and SLE were significantly more likely to have diarrhea, abdominal pain, nausea/vomiting, recurrent oral aphthosis, and anemia.Conclusions: The results of this study suggest that a significant association is present between CD and SLE. We found a prevalence of 3% for biopsy-proven CD in patients with SLE, which is five times the prevalence of CD in the general population.